REGISTERED NUMBER.. 07251522 CHARITY NUMBER.. 1139367 THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY (A company Ilmlted by guarantee) FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Page Reference and admln15tfatlve Informatlon Trustees, Report Independent Audltor's Report 8-10 Stat8m8nt ol flnanclal actlvltles Balance Shfrot 12 Notes to the Flnanclal Statements 13-21
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2026 REFERENCE AND ADMINISTRATIVE INFORMATION Charlty number.. 1139367 Company numb•T.' 07251522 Regl$lered Ofll¢g'. 16 Great Queen Street Covenl G8rden London WC2B 5DG Prlnclpal Offlco.. Medical microblolY Aberdeen Royal Infirtnary Ab&rdeen AB25 2ZN Scotland, UK Trustees: Professor Geoffrey Coomb5 Professor Souh8 K8nj Professor Heiman Weriheim Professor Anuradh8 Chowdhaty Or David Jenkins Perth, Australla Beirul, Lebanon Nijmegen, Neth8rtand5 Loughborough, England Chlel Ollicer Executlv& Dr Fiona Ma¢Kenzle Audltor Atels Audit SeNices Chartered Accountants 5th Floor, 16 Gr8al Queen Streel Covenl Garden London WC2B 5DG Investment Manager Ralhbon& Inv85tmenl Manager Limiled 8 Fin5bury Circus London EC2M 7AZ 8ank8r Th8 Royal Bank of Scotland Aberdeen Business C8nire Aberdeen Queen'5 C1059 Branch 40 Abyn Place Aberdeen AB10 1YN Sollcltor Ledingham Chalmer$ LLP, Solldtors Johnston8 Hous8 52-54 Rose stet Aberdeen ABIO 1HA Page 1
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 The Trustees present their annusl report and financi815t818rnents of thg Charity for the year ended 31 December 2025. The finanaal statements have been prepared in accordance wilh the accounting policies sel out in nole 2 10 the 8ccounls and comply rith the Charities Act 2011, Companies Act 2006 and the Statement ol Recommended Pr8¢11. Accounting and Reportino by Charities applicable to charities IFRS 102118ffecliv8 January 20151. OBJECTIVES AND ACTIVITIES To advance th8 education 8nd the Scien of therapy ol infection through Ihe eslablishmenl ol an inleinalional federation of affilial8d national and rIOnal societies with similar aims and objectives to those ol the Charity. In meebng the objectives, the charitable company shall.. 81 Piorno18 th8 conduct of sents¢ re8e8rch, convening international coryresses, CnIeren$ and symposia. bl Encourage Ihe co-operation of the members of the Charity Ilhe °Members'l 8mongsl th8mselv88 and bettveen scientists belonging lo societies dealin9 wilh r81ated b8sic and clinical sci8nc88 cl Encourage the formation ol nakn'onal and regional societies interested in therapy of infeclion in those countries or areas where such groups do not othetwse exist. dl Encourage andlor sponsor the formation ol international working groups lor special research. trainino projects or the use ol therapeutics in the field of Enti-inf8cb"v8 Ih8rapy anis co-ordinating their a¢tiMties. el Produce, publish 8nd distribute Iwh81hef graluilously or noll or to make 9fanls towards Ihe costs ol others produring. publishing ordislribuling material in any form including journals, books, pamphlets, feports, films, takes, progiammes or web-based maleiial that rn8y b8 de8med desirable for th8 furih8r8nce or promotion ol the Objects or lor the purpose of informing contributors and others of the need or piogress ol the Charity Aw8rd scholarships and bursaries r8ised from third party contribution5 to enable attendance at 8nd travel to any inlern8lional congfesses organised by the Chanty by pe150ns desetwng of such assis18nce as shall be decided at the discretion of th& Dir8clors and ExeGutsve Committee. The pollcle8 that have been adopted In order that the oblectlv69 arè mot ar•.. al The biennial Inlernalional Congiess ofAntimicrobial Ch8motherapy IICCI is held in major cities throughout the world. According lo the ICC schedule, the nexu34 ICC will be held in Manila, Philippines Ifom 7 to 9 Derntser 2026. bl The Executs"ve Commilleè holds quartedy m881ings to appraise the activities of ISAC and lo receive reports Irorn Ihe Tru51ees. cl Working groups may be lomed to 8ddtys5 curf8nl Issu88 with reg8rd lo anlimicrobial ¢hemolherapy dl The highe81 ISAC Award (the Harnao Umezawa Memorial Award) given at every ICC is donated by the Microbial Chemistry Research Foundalion, Japan. There is an oulrighl grant ol a sum ol money, together with a rtifiCate and me<Sal lo the reapienl. The Charity has established 'Young Invesligalors Travel Awards. to be given at every ICC lo desemng participanls presenting original work to allend the ICC. The'Torn B8rgan Mernorial Fund, w83 eslablished in July 20013nd Ihe'John David Wlliams Memorial Fund. was established in 2UU5. Ihese Funds each provide two travel grants enabling deserving young invesli981ors presenting original work to allend the ICC. el Publicalion5'. Th8 Charity publishes th8 Intemational Journal of Antimicrobial Agents IIJAAI12 volumes with 12 issues peryearl and the Journal ol Global Anlimicrobial Resistan IJGARI which is published quarterly. ISAC 8ssisls Member Societies in National and Regional Meeting8. gl Mernbgrship.. ISAC has 107 affiliated Member-societies. There are no membership lees. h) Finances.. Hisloncally, thew havo been two main revenug streams ol the Charity. The first is the surplus I souety sh8ie in the oiganisation of th8 biennial ICCS. The profils from ICCS are generally shared with the loc81 M8mb8r-Society liesl. In recent years however, including 2024, the ICC has made a loss and has cost ISAC rnoney. The second source ol income is royalty payments from Ils joumals,. IJAA and JGAR. The Chaty h8s appoin18d an Investment Manager who advises and generates revenue from the Charity's assets. Th8 revenue obtained shall be used in the yearly expenditure ol the Charty. Pag8 2
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 ACHIEVEMENTS AND PERFORMANCE Developments and actlvltles for the year 2025 al The ISAC Officers and Execulive Committee rnembers during 2025 are detsiled below.. Pr@sld8nt S. Kanj ILebanonl 2024- 2028 Pr851dent-EleGt H. Werlheitn INeth&rlands1 2024- 2026 Secr8tary-Gen8r81 A Chowdhary Ilndial 2024- 2028 Hon Treasurer D. Jenkins IUKI 2024- 2028 Immedlate Past Pr@sldenl G. Coombs IAu$lralial 2024- 2026 Ordlnary members R. Betba (Philippi$} M Dav IUSAI M. F8lcon81118lyl P. Munoz (Spain) K. Yanagihara (Japan) 2022- 2026 2024- 2038 2024- 2028 2022- 2026 2024- 2028 Ex-offlclo members IJM Editor in Chief JGAR EdiloT in Chief Chlef Exe¢ubve 0er 2024- 2026 2024- 2028 APSCMI repre5enlalive Young invesb'galor representative A. Tsaklls (Greecel F. Ma¢Kenzie IUKI J. Munila (Chilel S. Essack (South Afric81 O. Lye (Singapore) J. Zhao (Auslralial bl Trustee fa-tO-faCe meetings took place in London in February 2025 and Auslria in April 2025. Month meèbngs held via Microsoft Teams also took placè. cl ISAC conb.nued ils online webinar proJfamme. The following We held in 2025.. 8acleriophage Iher8py.' where are we now? Artifiaal intelligence in Anti-lnleclives D8rwin m88ls the £ntibiotic crisis Anlimicrobial stewardship in critica1 care units Emerging and re*merging inleclions among migrants Innovations and challenges in HIV prgvention and cur8 Managing MDR infections in the ICU.. anlibiolics, therapy duralion and immune modulation Oplimising Anb"microbi81 Th8r8py in Cnlical Care. From Levels lo Outcomes WHO fungal priority pathogens list. challenges in diagnosis and rnaTrag8m8nt Establishing the Role ol Inleclious Diseases & Clinical Microbiology Societies Page 3
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 ACHIEVEMENTS AND PERFORMANCE-contlnued dl Publlcatlon8'. InteTnatlonal Journal of Antimicroblal Agents The edilon81 orrice is situated in Elsewer's offices in Oxford, UK. All aspecls of joum81 praduchon are handled Vl8 the electronic Elsevier Editorial System IEESI. The number ol submissions to the journal continue5 to increase significantly as has the workload ol the Elyitor in Chief. A contract was enler8d into b&88 ISAC and EI88M8r is eff8cliv8 from 1 January 2020 to 31 DecTrb8r 2024. It automatically renewed lor three years until 31 December 2027. Elsevier have a direct conliacl wilh the IJAA Edilor-in-chiel, currently Profèssor Jan Li IAuslralial and pay him direct. His current contract runs from 1 January 2025 to 31 December 2027. In 2025, the Impact Factor for IJAA increased from 4.6 to 5.0. IJM is now ranked in the following posilions in the Journal Citalion Reports.. Inf8clious Di8e8ges 23 1141 journals Microbi01ogy 47 1167 journals. Pharmacology & Pharmacy 701356 joumals. IJAA Is sn online only journal. Journal of Global Antlml¢roblal Reslstance IJGARI In 2013 ISAC launched a seconcs journal,. the Journal ol Global Anlimicrotiial Resistance IJGARI. The lille is 100U/o owned by ISAC which enlefed Into an initial five-year publishing agr&ernenl wilh Elseviei Ltd. The Initial contiacl expired in De1mber 2019 and automatically rolled over for a further Ihree-year period until December 2020. ISAC and Elsevier renewed the conlracl early. effe¢live from 1 January 2020 10 31 December 2022. It automatically iollecl over and now expires on 31 December 2028. ISAC has a direct conlfacl with the JGAR Edilor-in-chief, currently Professor Alhanasios Tsakiis IAlhens. Greece) and pay5 him direct. H15 conlfacl tuns from 1 October 2024 to 31 December 2026. In 2023 the Impact Factor increased Ifom 3.2 to 3.7 and il is now ranked in the following positions in the Journal Citation ReportS'. Infectious Diseases.. 44 1141 journals. Pharmacology & Pharmacy.. 120 1356 journals FINANCIAL REVIEW Overall income lor the charity was £360,070 l£nil restricted income) in 2025, compared to £335,087 l£nil restricted income) in 2024. The increase in unreslricted income is mainly due to IncaSer1 journal royalty income. The charity exp8ns8s for th8 y88r w8re £275,355 lof which £nil was reslrict8dl. comp8r8d lo £329,905 lof whieh £9,393 was restri¢ledl in 2024. R8serv88 The applicalion ol the Charity's funds lor 2025 is as presented in the accompanying audited accounts. The balan at 31 DeTrmber 2025 is £5.944,83712024. £5,260,442). Al the 31 Decemb8r 2025 th8 charity had 3 designaled funds lolalling £40.71812024. 5 101811ing £115,396) and 1 reslri¢led fund tolalling £1(b,76812024.' £106,768). See note 16 to the finanaal statements lor more dètails. R8serves Pollcy The policy ol the Trustees is lo maintain reserves at a minimum level of £1,000.000. This provides sufficient funds to cover operalional costs and respond to emergency costs. Planning lor the bi-annual Conofesses OCCUfS several months in advanc8 This means co8ls are incurred well before th8 congr85s lak8s plac8 8nd non-atlendance due to exceptional circums18ncAs c8nnol b8 piedi¢led. Th8 Charity aims lo keep suffia8nt in reserv8 to cover 8ny unlofeseen congress costs. Page 4
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2026 FINANCIAL REVIEW- continued Investment Polley The objective has been lo provide capita1 growth and also to generate income for charitable purposes. The achievement ol the policy 15 nionilored through discussions with th8 investfflent manag8rs and me85uiemenls against appropriate benchmarts. The Trustees are sabsfted with the ad given on slfalegy and minimising risk. ISAC'S 8thie£l nveStrnenI policy $peryficAlly exdudes companies known lo be dealing in tobacco, arms, alcohol and gambling and also excludes pharmaceutical companies due to the conflict ol inlefesls. The policy ol the Trustees is lo maintain the investment balan at a minimum level of £3,500,000. Investment Perfomiance Thè inv85tsn8nt portfolio at 31 De(bar 2025 had a total a5S8t valu8 of £5.120,379 compar8d lo £4,490,879 in 2024. Fixed Interest Equity 18.72 UK North Affl8rica Japan Europe Asi8 Pa¢ific Emerging Markets Global Inveslmenls Actively Managed Slr818gies Commtsjities Cash Total 24.10 28.13 4.03 5.99 251 1.68 6.67 2.28 3.46 2.43 100.00 Risk Managemen¢ The major risks lo which the charitable company is exposed, as identified by the Trustees are under a continual prO$S ol review and procedures ar6 In place to managè thosè risks. Piole5sional indemnity insuranc6 is piowded for the org8nisalion. FUTURE PLANS During 2025, ISAC continued lo progress engagement with ils Executive Committee members lo deliver the soaety strategy in an inclusive I transparent way. ISAC undertook a"slrategy rewe in Septembei 2025 In Athen5. As a COn58quence of that meeting. ISAC is currently recruiling an additional member of stsff to join the ISAC office, lo progress strategic priorities idenlified al the meelirvJ. In 2024. ISAC delivered ten live webinars as part oflhe online'lSAC Acadernf and plans tOntinue Ihis successfvl ISAC is partnering with one of ils Member Socielies, the Philippine Society for Microbiology and Inleclious Diseases, lo deliver the 34 Icc in in Manila in oember 2026. Having soliated bids. ISAC is currently looking lo identify a suitable Memb8r Society lo co-host the ICC in 2028. ISAC made available a number ol proiect grants and souety grants in 2025 and plans to continue this initiate. ISAC continues lo develop the ISAC Anlibiolic Tre8lm8nl Guidelines.. an open acrsss onlin8 antirri¢robi81 trealment guideline. 11 was launched in September 2024 in collaborglion with Radboud university medical cenlre (Radboudumel, thè Netherlands and the Amèrican UnN6rsity of Beirut Medical C6ntr6 IAUBMCI 8nd will Ir8nsition rully ov81 lo ISAC by 1 January 2028 Page 5
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 STRUCTURE, GOVERNANCE AND MANAGEMENT The Inteination81 Society of Antimicfobi81 Chemolher8py (previously The International Society for Infection and C8ncerl IISACI is 8 company limited by guarantee incorpofated on 12 May 2010 and registered wth the Chanty Commission on 20 December 2010. ISAC operates under the tules s81 out in Artic18s Association, which w8re updated on 2 Oclober 2017. The Ch8rity has £ssociated Member Societies throughout the world. The Trustees are the saety Pr8sid8nl, Piesidenl-Elecl, Immediate Past President, Secrelary-General and Honorary Treasurer. Publlc benellt The Trustees have considered the Charities Comrnission's requirement in SpeCt ol Public Benefit. In their view the Charity meets. in full, the criteria lo satisfy the lest. The Trustees, have d85CFibed earfi8r in this report Ihe aclivibes undertaken to further Ils chsnlable purposes foi the public b8nefit. Tru8tees The Executive Offir$ ol the Society work volunlariSy for the Charity. They 8r8 g8n8r8lly p£id employ888 of univ8rsilies or hospitsls in their own covnlry or are reliied lfom paid employment and have limited resour$ and lirni18d lirne for the Charity. The Charily supports these Officers In terms ol help In funding trave in connection with the Charity's work and in line with Ihe Chanty'5 financial guideline5 le.g. Me8ling8 on progr88s of congr8SS85, on Publications, arF(I with Investment Adw5er5 and Bankers). Pagè 6
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY TRUSTEES ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 STATEMENT OF TRUSTEES. RESPONSIBILITES The trustees (who are also directors of The InteiTralional Society ol Antimicrobial Chemolherapy for the purposes of company lawl ale ie5ponsible lor preparing the Trustees. Annual Report anrl the financi31 statements in accordance wilh applicable law and Uni18d Kingdom Accounting Standards Iuniled Kingdom Generally Accepted Accounting Piaclicel. Company law requires the Ituslees lo prèpare financi81 statements lor each finanal year, which give a tru9 8fKI [811 wèw of the slate olaffaiis ol the charitable company and of the incoming r850uice5 and applical'on ol resources, including th8 income and expenditu, ol the charilable company for that period. In preparing these finanoal slalemenls, the trustees are reouir8d to.. select suitable accounting policies ancl then apply th8rn COnS15tenlly, observe the methcds and principles in the Charities SORP 2015 IFRS 1021.. mak8 judgements and ests"mates that are reasonable and prudent.. stale whether applicable UK Accounl'ng Standard8 have been followad. subject lo any material departures disdos&d and explained In the financial stalemenls., prepare the f nancial statements on the going conrn basis unless it is inappropriate to presum8 that the charitable company will continue in operation. The trustees are responsible for ke8ping adequ81è accounting records that disclose with reasonab18 accuracy at any tim& lh8 fin8ncial posits.on ol the charitable company and enable Ih8m to ensure Ihat the financial statements comply wlh the Companies Act 2006. They Bre also responsible lor safeguarding the assets ol the charitable company and hence lor taking re8sonab18 Steps for the prevention and detection ol fraud and other irregul8riti&s. In so f8r a5 the Iru51eès arè aware.. there is no relevant audit information of which the charitable company's auditor is unaware,. and U)e trustees have taken all steps th81 they owht to h8V6 taken lo make themselves aware ol any relev8nt audit informalion and to establish that the auditor is awar8 of that inlomiation. Approved by Ihg Truste85 on 'Lg gq 201 and signed on lh9ir behalf by Dr David Jenklns Treasurer, Director and Trustee Page 7
INDEPENDENT AUDITOR'S REPORTTO THE MEMBERS OF THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY FOR THE YEAR ENOED 31 DECEMBER 2025 Oplnlon We have audited Ihe financia1 slalem8nls ol The International Socioty ol Ants"microbi81 Chemolher8py Ilhe 'chanlab18 company'l for the year ended 31 December 2025 which comprise th& Stal8m8nl of Fin8n¢i81 Aclivi118S, the Balance Sheet and notes lo the financi81 slalem8n18, including a sumrnary ol significant attounting polioes. The finanoal reporiing Ifamework th81 has b8en applied in their preparation is applicable law ancl United Kingdom Accounting Standards, including Fin8n¢ia1 Reporting Slarpdard 102 7he Financi31 Reporting Sl8nd8rd 8pplic8b18 Iri Ihe UK anrl Republic of Irelancl (Uniled Kingdom Generally Accepted Accounting Practic61. In our opinion the financial 518temerils-. giv8 a Ifue and fair view ol the slate ol the charitable comp8ny'5 affairs as 8131 D8cember 2025. and of ils in¢oming resources and appli¢alion ol resources, includin9 ils incom8 and expenditure, lor the year Ihen ended", have Leen propady prepared in accordan wilh United Kingdom GenerallyACpted Accounting Pract'ce," and havg been prepared in accordan with the requ1MentS of the Companie5 Act 2006. Basls for oplnlon We conducted our audtt in accord8nce with Inlernaliona1 Standards on AudilirKJ IUKI IISAS IUKII and 8pplicable law. Our responsibilities under those standards are further described In the Audilorfs responsibililie8 for Ihe audit of the finan81 slalements section ol our report. We zre independent of the charilable company in accordance with Ihe ethical requiiemenls Ih818re relevanl lo our audil ol the financial slalemen15 In the UK. including the FRC'S Elhical Standard. 8nd w8 hav8 fulfilled our other ethica1 iesponsibililies in accordance with these requirern8nls. We b81i@ve Ih21 the audit eviden we have oblaine(S is suffioenl and appropriate lo provide a basis for our opinion. Concluslon5 rolatlng to golng concern In aSiting the finan81 stslemenls. we have concluded that the Irustees, use of the going conc&rn basis of accounting in the prepar8lion ol Ihe finanual slatemenls is appropriate. Based on the work we h8ve pertotm8d, we hav8 not identified any material Unrtain"es relating lo evenls or conditions that, individually orcolleclively, may cast significant doubt on the charitable cotnpany's ability to continu8 85 8 going cOnrn lor a period ol at least twelve monihs from wh8n th8 financial statements are aulhorised lor 18SU8. Our respon5ibili118s and th8 responsibilities ol the Iruslees wilh respect to golng concetn 8r8 d8scrib8d in th8 r818vanl se¢lions ol this report. Other Informatlon The olhei information cornpllse$ the inlormalion included in the trustees annual report, other than the financial st8lem8nl8 and our auditor's report theon. The Iruslees &re responsib18 for the other information contained within the annual report. Our opinion on Ihe financi8151alement5 does not cov8r the other inlormalion and, except to the exlenl olherwise exp1icilly slated in our report, W8 do not express any form ol assuran conclusion Ihereon. Our responsibility Is lo 188d the other infomialion and, in doing so, consider whether thè olhei information is materially inconsislent with the financial slalemenls or our knowledg8 obtained in th8 cours8 of the audit or 01heiSe appears lo be materially misslaled. 11 we identity such material inconsistencies or apparent material misslatemenls. we are reouired to detemine whelhei this giv85 rise lo a m8leri81 misslalemenl in thè financial slalemenls themselves. 11, based OFI the work we havo perforrned, we con¢lude Ihat there Is a material mi&slalement of this other infotrn21ion, w& are required to report that fact. We have nothing lo part in this regard Oplnlon8 on other matters prescilbad by th& Compan185 Act 2006 In our opinion, based on the work undertaken in th8 eOUIS8 of the 8udil' the inforrnalion given in the Iruslees. report lincorporaling the directors, report) for Ihe financial year foi which th8 fin8nci81 slalemenls are prepared is consistent with the financial st8181ll8nts,' and the directors, report has been prep8red In accordanc8 wth 8pplic8ble gaI requirements. Page 8
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY FOR THE YEAR ENDED 31 DECEMBER 2025 Matters on which we are required to report by axceptlon In (he liqht ol the knowledge and understanding of the tharitab18 coTnpany and its Ènvironment obtained in the course ofthe audit, we have not identified material misslatemenls in the directors, report. We have nothing to report in respect ol the following matters in relation lo which the Companies Act 2006 requires us to report to you il, in our opinion.. aclequ8le accounting records have not been kept, orfelurns 2dequ8te lor our8udil have notbeen received from branches not visiled by us., or the frnancial statements are not in agreement wilh the accounting records and returns., or certain disclosures ol directors, remuner81ion specified by law 8re not m8de', or we have not reiVed all the inform8tion and 8xpl8nalions we r8quire for our audit- or Ihe Iw5tees were not enlilled to prepare the financial statements in accordan with the srnall companies, regime and take advantage of the 8m811 compani85' exernplions in pieparing the directors, report and from the QUIreMent to prepare a strategic report. Responslbllltles of trustee8 As explained more fully in the trustees, responsibilit$ statement set out on page 7, Iwsle88 (who 8ra also the directors ol the charitable MpanY foi the purposes ol company lawl a responsible for the preparation ol th8 financial statements and lor being satisfied that they give a tru8 and fair Nq8W, 8nd for such internal control as the trustees delefminè is ne$sary lo enable the preparation ol financial slalements that ar8 fr88 from material misslatemenl. whether due to fraud or error. In preparing the finan81 slatemenls. the Ifuslees are responsible lor assessing Ihe charitable company's abiltiy lo continue 8$ a going concein. disclosing, as applicable, matters related to going conrn and using the going concem basis ol accounting unless Ihe Iruslees eithgl intend to INuidale th8 chatab company or to Cease 0ratIOnS. or hav8 no realistic all8rnatNe bul to do so. Audltor's re8ponslbllltl85 lor the audlt of the flnanclal statements Our objectives are lo obtain ieason8bl8 85SUf8nc6 sboul whether the financial slalemenls as a whole are free from materia1 misstalemenl, whether due lo fraud or error. and lo issue an auditor's report that includes our opinion. Reasonablè assuran is a high level ol assurance, bul is not a guarantee that an audit conducted in accordance with ISAS IUKI will always d818cl a rn8lerial misstatement when il exists. Misstalemenls can arise from Ifaud or error and are consKJered material il, individually or in the 8ggregale. they wuld ressoablY b8 8xpecled to influence th8 econornic d&ci5ions ol users taken on the basis ol these financial slalements. Irregularits"es, induding Iraud, are instances of non-¢ompliance wilh18WS 8nd regulations. W8 design procedures in ling with our responsibilities. outlined above, to detect material misslalements in respect of irregularities, includin9 fraud. The specifi¢ pro¢eduf8S for this engagement and Ihe extent to which these are capable ol detecting irregularits-es, including fraud is detailed below.. Enquiry of m8n8g8ment and those charged with goVernaTr around actLial and potential litsgab'on 8nd claims as well Bs actual, suspected and all8g8d fr8ud, Reviewing rninules ol meetings ol those charged with governance., Assessing the extent ol Complian with Ihe laws and fegulalions considered lo have a direct material effect on the finanual statements or th8 op8r8lions of the company through enquiry and inspection.. ReM8wing financial statement disclosures and lesling lo supporting documentation to 8SS8ss compliance with applic8bl8 laws 8nd regulalions., Performing audit woth over the risk of m8nag8mènt bias and overde ol controls, including tesling of journal entries and other adjuslmenls lor appropriateness. evaluating Ihe business r81ionsle of significant transaclions oulsid8 the nortnal eourse ol business and reviewing accounting estimates lor indicators of polenlial bias. 8eeause ol the Inherent limitations ol an audit, Ihere is 8 risk th81 w8 will not d81ect all irregularikn'es, includlng those le8ding lo a mateiial mis51atement in the financial statements or nOnMplIan wilh rul8On This risk incr8ases the more that compliance wlh a law or fegu181ion is mOVed from the events and Irangaclions (eflecled in the financial slatemenls. as we will be less likely lo become awaie of instances of noTr-compIian. The risk Is also gr88lei reg81ding irularl"eS occurnno due to lfaud rather than error, as fraud involves intentional cono88lment, forgery, collusion, omission or rnisrepr838nlation. A further description ol our responsibilities is available on the Financial Reporting Coun(1,8 website at.. hllps.'Ilww.Ir¢.org.uklOui-WothlAudiUAudil-and-asSuianIStandards-and-gU1dan1Sland8[dS-and-gUidan¢- lor-auditorslAuditors-responsibijilies-for-audiVDèscriplionf-au1lors-responSlblliIleS-fOr-audIt.aSpx. This description fomis part ofour audilof5 report. Pagè g
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE INTERNATIONAL SOCIETY OF ANfiMI¢ROBIAL CHEMOTHERAPY FOR THE YEAR ENDEO 31 DECEMBER 2026 Use of our ieport This report is made solely to the chaiilable company's members, 3s a body, in accordan with Chapter 3 01 Part 18 ol the Companie5 Act 2006. Our 8udil work has been undertaken so that we might slate to the charitable cornpany'5 members Ihose maller8 we are required lo slate lo them in an auditor's report and for no other purpose To the fu118818xlenl permilled by law, we do not atpt or assume responsibility 10 anyone other Ihan the charitable company and the charitable company's memb8rs as a b¢W, for our audit wotk, lor this report, or for the opinions we have formed. kn_LLJ John Howard (Senior Statutory Auisitorl For and on beh811 of Az8t8 Audit Ser4ices Slatulory Auditor. Chartered Accountants Floor, 16 Great Queen Slr88t Covenl G8rd8n London WC28 5DG Page 10
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY STA TEMENT OF FINANCIAL ACTIVITIES IINCORPORATING THE INCOME AND EXPENDITURE ACCOUNTI FOR THE YEAR ENDED 31 DECEMBER 2025 Not•¥ Unrostrlotod Fund$ Restrlcted Fund5 Total 2025 Total 2024 Income from: Charitable Activities Investment Income 272.620 87.250 272.820 87,250 253,908 81.159 Total Incomlng re8ourc8 360,070 360,070 335.067 Expendlture on: Raising Funds Charitable activities 19,618 255,737 19,618 255,737 18,001 311,W4 Totsl resourc9¥ expendèd 275,3S5 276,355 329,905 Net Incomellexpenditur•l before Investment galns 84,715 84,716 6,162 other recognl8gd galns Foreign exchange gainslllossesl Gain5 on investment assets.. Realised gainslllossesl Unrealised gainslllossesl 12.099 12,099 110,8961 10 164,427 423,154 164.427 423.154 32.312 352.097 599,680 699.680 373,513 Nat movament In funds before transfer8 684,395 684,395 378,675 Transfer behveen ndS Net movémènt In funds for the year 684.396 684,355 378,67S Reconclllatlon ol funds.. Total fvnd8 brought fotward 16 5,153,674 1[,768 5,260.442 4,881,767 Total funds carried forward 16 S,83B,069 106,768 6,944,837 5,260,442 All the above amounts relate to Continuing activitiès. There were no recognised gains and losses other than those slated abovè. The notes form part ol thesg finan81 5tstemenls. Page 11
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY BALANCE SHEET (Company number 072615221 FOR THE YEAR ENOED 31 DECEMBER 2025 31 December 2025 31 Decemb&r 2024 Notes Flxod as8ot8 Inveslmenls Tangible fixed assets 10 5.120.379 1,790 4,490,879 1.518 5,122,169 4,492,397 Cv¥ient assets Debtors Short term deposits Cash al bank and in hand 269,874 127,183 495,349 244.718 101,213 S44,1 13 892,408 890,892 Credltors.. amounts fallin9 du8wlhin one year 14 169,7381 1122.8471 Net current assels 822.668 768.045 Not as88l8 15 5,944.837 6,260,442 Uniestrlcted fund General Funds Designated Funds Restricted Funds 16 16 16 5,797.351 40,718 108,768 5,038,278 115,396 106.768 6,944,837 5,260,442 Thg financial slalemenls havè been prep8red in accordan wilh the speci81 provisions for small companies under Part 15 of the Companies Act 2006. The financi81 slalemenls were approved by the board of Truslees and aulhorised lor is5U8 on I,? and signed on Iheif behalf by". [¢391 Dr David Jenklns Tiea5uier, Dir8¢1or and Tiuslee The noles fomi part of Ihese finanaal slalements. Page 12
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 202S GENERAL INFORMATION The International Society of Antimierobial Chemotherapy is a charitable company, limited by guar8nlee, registered In England and Wales. The company's registered number. the charity's registered number and the regislered office addres5 can be found on the charity information on page 1. Th& chgrilable company's prinaple pla ol business Inoled in the charity information on page 11 differs from the registered office. Th8 n8lure of the charitys operations 3nd prinupal aclNities 8re set out on page 2. In the event ol the charity being woutKf up the Ilabllity in respect ol the guarantee is limited to £1 per member of the charity. ACCOUNTING POLICIES The prinapal 8¢UntIng policies adopted. judgements and key sourrRs of 8stimats.on unrtainlY in the pparatIonS ol the financial slal8m8nls are as follow.. lal General Informatlon and basis of preparation Th8 fin8nc4al slalemenls have been prepared in xceord8nc6 with Accounting and Reportiry by Ch8rilies.' Slalement of Recommonded Pfattice applicable to charities prep8ring their accounts in accordan with the Fsnancial Reportin9 Standard 8pplicable In the UK IFRS 1021 issued on 16 July 2015 las updated through UOale Bulletin published on 2 February 20171. the Financial Reporting Standard applicable in the United ngdoM IFRS 1021. the Charities Act 2011, the Companies Act 2006 2nd UK Generalty Accepted PracU'Tr as it applies from 1 January 2017. The charitable company eonstitutes a public benefit entity 85 defined by FRS 102. The financial slalements are prepared on a going collrn basis under the hislofical cost convenb'on. modified lo include rtain lems at fair valu8. The financial statements are prep8red in Slerting which is Ihe functional currency of the charitable company. Ibl Golng Concern The financial slalemenls have be8n prepaied on a going Canrn basis as the Trusteès b81ieve that no mate81 uncertaintiès exist. The Trustees have consid8red Ihe lèvel ol funds held and expected 18V8101 income and expenditure foi 12 months from aulhorising these financial s18lem8nls. The budgeted income and expenditure is sufficient with the level of ieserves lor the charity lo be ablg to conb"nu8 as a going con¢xrn. Icl Funds Unreslricled fvnds - repr8sÈnl funds which can be used in accordance with thè charitable objects al the discretion ol the Trustees. Designated funds- these at8 funds sèt 89idè by Ihe Trustees out ol unreslricled general funds lor speufic purposes or projects. Reslricled fUS- represent funds that can only be used forparticular r85trict6(I purposes within the objec15 of lh8 charity. Reslriclions arise when spe¢if18d by the donor or when Ihe funds arg raised for sp8cIfic restricted purposes. Further explanation ol the nature and purpose ol each fund is induded in th8 notès to the financial slatemenls. Idl Taxatlon The charity 1$ 8xèmpt from corporation lax on ils charitable 8Ctiwties. Page 13
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2026 ACCOUNTING POLICIES - continued lel Income All income Is Includ8d in Ihe Statement ol Financial Activi1188 ISOFAI when the charity 15 legally 8nlilled lo the incorne 8fter 8ny perfom)ance conditions h8ve been rnel, the amount can be measured reliably, and il is probable that the income will b6 receiv8d. Donalions and legaci85 are recognised In the fin8ncial slalemenls when the Irusle85 81e convinced that there is entillemenl lo the income. there 15 cert8inty ol receipt and the atnount in question is Measurable. Income from thal£ble activities indudes income in relation lo conferences and Jouina1 Royalti8s Income earned from conf8r8nce8 $ included in the year th8 conference is held. Journal income 18 included in line with the financial year ol the charity. Investment income 18 earned through holding assets for investment purposes such as shares. 11 includes divendS and inleresl. Dividends are recogni8ed once the dividend has been declared and nolificalion has b88n reiVed ol the dividend clue. Th8 is normally upon notification by or investment advisor ol the dividend yield ol the investrnenl portfolio. Interest is included when receivable. lfj Expenditure Liabilities are recognised as expenditure as soon as the is a legal or conslruclive obligation committing the charity to that èxpendilur8 It 1$ piobable that selllement will be required, and the 8mount of the obaatIon can b8 rn88sured reliably. All expenditure is accounted foi on an accrual basis. All expenses including support costs and goveinance cosls are allocated or apportioned to the applic8bl8 8xp8ndilure headings. Cosls of raising funds consist ol inveslrnent management lees for th8 Period. Costs ol charitable activities consist ol those costs incurred by the charity in delivery of 115 activiti8s and seMc6s lo fvrther th8 charity's obje¢live5. Governance costs Include Ih08e in¢uried in the governanc6 of th8 charity and its assets and are primarily associated with constitutional and slalulory requirements. Irrecover8ble VAT is charged against the expenditure heading for which it was incurred. Igl Tanglble flxed assets Tangib18 fixed assets are slated at cost less acoumulated depreciation. Depieualion 15 piowded on all tangible fixed assets, at iales c8l¢ulaled lo write off the c05t of each asset on 8 Straighl-line basis Dv•.r the asset'5 eslim81ed useful lives ès follows-. Offfj equipment- 10% straight line Ihl Flxed a55et investments Investments afe a lom) ol basic fingncial inslrumenls and are Initially recognised al Iheir tiansatlion value and subsequenuy m888ured al their laif value as atthe balance sheetdale using the closing quoted market price. All gains and losses are taken to th8 Statement ol Financial Actiwti88 £s they arise. Realis gains and losses on investrn8nts are c8l¢ulated as the differenc8 b8tween Ihe sale prOed5 snd opening m8rk81 value Ipufchase date if lalerl. Unrealised gains and Ioss8S are calculated as Ihe diffei8nc8 beiween Ihg market value al the year end and openin9 market value lor purchase dale 11181811. The charity d065 not aUIre pul Opon$, clenvatives 01 olh8r complex financial Instrumènts. The investment in subsidiaries arè m8asur8d al cost less impaimiènl. P8ge 14
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 ACCOUNTING POLICIES- continued 111 Debtors Other debtors ale recognised al the setement arpounl due. Prepayments are valued al th9 amount prepaid. Accrued income is measured 81 thè amounl due to be re1ve. (11 Current asset inve5tmentslShort t&rm deposits Cuiienl asset investments are short18rm highly liquid investments and are held at fair value. These inclLKle cash on deposit and cash equivalents with a malufily of less than onè year. Ikl Cash at bank and In hand C85h at bank and cash in hand include5 cash and short term highly liquid inveslm8nls with a short matuTrty of thre8 months or less from the date of 8cquisib.on or opening ol the deposit or similar accounts. 111 Credltors Creditors are rewnised when the is a present obligation resulting from 8 past event that will prob8bly result in the Ifansler ol funds lo a third party and the amount due lo settle th8 oblwation can be measured or eslim81gd rèliably. Olhsi ¢reditors and accruals are recogniséd at their settlement amount due. Im) Financial instruments The ch8rity only has financial 8SS8ts and financial liabilities ol a kind that qualify as basic financial instruments. Basic financi81 instruments are initi811y recognisèd 81 transaction value and subsequently measured at their settlement value except lor bank loans which are sub58qU8ntly measufed at amortised cost using th8 effective interest method. Inl Forelgn currency Assets and liabilities in f018ign currencies are translated into sterling at the rates ol exchange ruling £1 the balance sheet dale. Trans8clions in fOIgn currencies are Ifanslaled into slerling 81 the rale ruling on th8 date of th8 transadion. All exchange differences are reneeted in the Statement of Finantral Acts"vities. lol Judggments and key sources of eslimalion uncertalnly Accounting estimates and judgements are continually evaluèted and are based on histOriC81 experience and other factors, including expectations ol future events that are believed lo be ièasonable under the circumsl8nc85. The following judgernents 18P8rt from those involving estimalesl have bèen made in the pro$ 01 applying the abov8 8ccounts.ng policies that hav8 had th8 tnost significant effect on amounts reeognised in the financ431 slalemenls". Uselul 8conomle lives of fangible assels The annual depreciation ch8ige lof tangible assets is sensib've lo changes in the estimated usèful economic lives and residual values ol the assels. The usefvl economic Iiv8s and residual values are re- assessed annually. They are amended when necessary lo reflect current estimates, based on technol(gical advancement, future investm8n15, economic ulilisation and the physical condition ol the assets. See note 11 lor the cairying amount ol the fixtures and eouiRKnenl and compulef equipment 8nd nolg12gl loi the useful economic lives lor each dass ol assets. There are no key assumptions cOnrnIng the future and oth8r key sources ol estimation uncertainty at the reporting date that have a SignifinI fisk ol causing a material adjustment to the [ryIng amounts ol assets and liabilit18S Within the next fin8nry81 year. Page 15
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 CHARITABLE ACTIVITIES Unrestrlcted Funds Total 2026 Total 2024 International cong$$ of Ch8molher8Py IJAA and JGAR Joufnal Royallies Olh&r Journal income 258.561 14,259 258,561 14.259 240,064 13.844 272,820 272,820 253,908 In 2024, all the charitablè aclimty inrx)m8 was allributable lo U)e unrestficled fund, INVESTMENT INCOME Unrestrlcted Funds Total 2026 Total 2024 Income from fix8d asset inveslmenls Inl818St on bank and short term dèp051t accounts 86,897 353 86,897 353 80,626 533 87,2SO 87,250 81.159 In 2024. all the investment income was attributable to the unreslrieled fund. RAISING FUNDS Unrestilct•d Funds Total 2026 Total 2024 Inveslrnenl rnanager lees 19,618 19,618 18.001 In 2024, 811 the irTrv8simenl income was attributable to th8 unr85lThcled fund. Page 16
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 CHARITABLE ACTIVITIES Unrestrlcted Restrlcted Funds Funds Total 2026 Total 2024 Expenses ofsociety meetings and publicity Execulive Offi expenses Sgcrelarial expen5e8 Journ81 costs Grants W8bsite costs Bank charges and foreign curffjnG movements Depreciation Sundry APSCMI costs Project and education81 International Congress ol Antimicfobial Chemotherapy Support of non-ISAC congresses Governance costs Legal and prof85siona1 Fe85 Str8le9y Rewew Executive office expenses- insuran Audit and accountancy lees Accounting subscriplion 31,571 63,983 43.118 19.331 45,296 2,048 31,571 63,983 43,118 19,331 45.296 2,048 27,954 61,159 42,692 17,016 57.221 2.410 418 330 586 36 3.292 418 330 586 1,036 262 212 120 3,236 3,292 124.6671 3,182 124,6671 3,182 73,663 6,537 15 47,555 5,560 13,752 346 47,555 5,560 13,752 346 4.715 13,656 255,737 265,737 311,904 In 2024, all tho ch8rilablè acliwty costs wèr8 allllbulabl8 to Ihg unr951ricled fund. NET INCOMING RESOURCES FOR THE YEAR 2026 2024 This is slated after cha(ging'. Auditors, lees.. Audit fee other non-audit fees Prior y&ar lov811 l und8r 8CCtu81 10,2(K> 2,986 912 330 9,600 2,520 1,536 262 Depreciation TRUSTEES EXPENSES Durfng the year 5 12024.. 71 Trustees were reimbursed £23,929 12024". £28,248) lor travel and other ècessary costs incuiied during th8 year in Connection ryth thè work of th8 ch8rrty. The Trustees recelved no remuneration lor their sem$ during this year or thè pr6Mous period. STAFF COSTS DuTrng the y88r, ISAC employed 1 p8f8on 12024.. 11. The salary c0518 of £38,438 12024.. £38,012) is included wthin secretarial exp8n8es. Th&re wère no employees 68rning abovè £60,0(K) pèr annum during Ihis yèar or Iha prior pèriod. Included within executive offi expenses are ¢osts 01 £63,451 12024.. £60,627) recharged from NHS Giampi8n foi the Charity'5 share of the s818ry of the Chief Execulive Office for lim8 Spent working on the Charity. In 2025, management lees of £4,68012024'. £4,680) were invold by Aceofd Business Partnerships relating lo secretarial assistance lo the ISAC CEO. Page 17
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 10. FIXED ASSET INVESTMENTS 2026 2024 Quoted inv88tm8nt8 Market valuè at 1 January 2025 Additions Disposals Realised investment gainslllos5e51 Unrealisèd Invèstmènt 9ainsll105S881 4,490.879 1,396,644 11,354.7251 164.427 423,154 4,064,213 352.922 1310.6651 32,312 352,097 Market value al 31 December 2025 6.120,379 4,490.879 2026 Market Value 2024 Market Value C08t Cost Fixed Interest UK Equities Overseas Equilie5 Allerllaliv8S 945,778 655,118 1.471.728 252,237 982,337 1.207.744 2,571,974 358,324 658.5D9 831,483 1,186,202 438,419 657,458 1,176,057 2,093,070 564,294 3,324,861 5,120,379 3,114,613 4,490,879 In 2025 Ihere were no12024'. £nill inveslmenls in thè yoar that r8pr888nted 5Q/) ofth8 manag8d portfolio 8t the yèar-ènd. TANGIBLE FIXED ASSETS Olllce equlpment Total Cost Al 1 January 2025 Additions 3,770 602 3,770 602 Al 31 Decernbgr 2025 4,372 4,372 D8preclation Al 1 Janu8ry 2025 Charge 2,252 330 2,252 330 Al 31 D8cember 2025 2,582 2,582 Net book value At 31 Oecember 2025 1,790 1,790 At 31 December 2024 1,618 1,518 P£g8 18
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 D8cernber2025 12. DEBTORS AND PREPAYMENTS 2025 2024 Trade debtors Prepayments and acLrued income 80 269,794 244,718 2S9,874 244,718 13. SHORT TERM DEPOSITS 2025 2024 Amounts held by sl¢)ckbrokers 127,183 101,213 14. CREDITORS.. AMOUNTS FALLING DUE WITHIN ONE YEAR 2026 2024 Other creditors and awruals Tr8de Creditors 69,738 118.317 4,530 69.738 122,847 15. ANALYSIS OF NET ASSETS BETWEEN FUNDS- curr&nt year Tanglble flxed assets and Inve$lm8nt$ Curr8nt assets Total General funds Designated funds Restricted fvrKIs 5.722,169 675,182 40.718 106.768 5,797.351 40.718 108.788 6,122,169 822,668 6,944,837 15.1 ANALYSIS OF NET ASSETS BETWEEN FUNDS- prioryear Tanglblè flxèd assets and Investments Current as$et8 Total G6n&r81 tunds Designated funds Reslricled funds 4,492,397 545,881 115.396 106,768 5,038,278 115.396 10S.768 4.492,397 768,045 6,260,442 Page 19
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 16. FUNDS The movement ol fvnds in the current year are as follows.. Inveslm8nl Forol9n gxchangB g41N51 IIos8esl Balance at 31.12.24 Incomlng resources Outgolng r9s0urces TranslerB Balancè at 31.12.25 11055951 Restrlcted funds.. European Congress ol Chemolheiapy 106,766 106,768 Deslgnated fund8'. Tom Beigan / JD Williams ICC Travel Grant general fund Iformerty the Inlefnalional Co-opeialion Fund) BSI Working Group UTI Working Group 14,089 114 14,203 16.925 239 17.164 75,490 8,892 3,900 179.3901 459 9,351 115.398 353 4,359 179,3901 40.718 Unrestrlct8d fund.. General lun 5.038,278 359,717 1275,3551 587,581 7,740 79,390 5,797,351 6,260,442 360,070 1275,35SI 587,S81 12,099 S,944,837 The movement ol funds In lh8 prtor y68r ar6 as follows.. Investment galnsl 11055fj51 Forelgn gxchangg Balanco al 31.12.23 Incomlng iesourGe5 Ouigolng resourcfr5 Transfers 8alance ai 81.12.24 Ilossgsl Restated Restated Reststed Restrlcted funds.. European Congfess of Chemotherapy 118,161 19,3931 106,768 Deslgnat6d funds: Tom Bergan JD Willi8ms Tom 8eioan l JD William5 1,821 13.982 11.6?11 114.2081 226 11.7401 15,829 14.089 Co-operalion Fund BSI Working Group UTI Working Group 21,143 78,992 9,304 307 14.5251 16,925 75,490 8,892 13,5021 14121 125,042 533 16,2651 13,g141 115,396 Unrastrictad fund.. General nd 4,640,564 334,534 1314.2471 384,409 16.9821 5,038,278 4,881,767 33S,067 1329,9051 384,409 110,8961 5,260,442 Page 20
THE INTERNATIONAL SOCIETY OF ANTIMICROBIAL CHEMOTHERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2026 16. FUNDS Icontlnuedl Restricted funds The UK based charity'"Europe8n Congiess of Chemotherapy IECCI. wound up during 2019 and tr8nsferied its fund5 to ISAC. On receipt of this money ISAC agreed to form a European Wort(ing Group. Ils primary objectives are.. Continue the activili8S 8nd tneetings of th8 South Eastern Congress of Chemotherapy, The ofganisation and administration of European Surnmer Schools and assoualed themed meetings., and uenerally, the promotion ol and furth8ianc8 of thg objects ol ECC. Designated funds The Tom Bergan Memonal Fund and the John David Williams Memorial Fund were established in 2001 and 2005, respeclively, to provide travel giants lo young investigators presenb.ng original work at the ICC. During 2024, the two funds were merged lor accounting and reportin9 purpose5. Accordingly, the pnor year comparakn've figures have been restated lo reflect thg combined fund balance and activities. In addition. travel awards lo18lling £1.740 awarded in 2024 from the meroed fund were Incor clly charged lo the General Fund. The 2024 figure5 have therBfoi8 been iesta18d to CQFreclly 8llocale these awaids lo th8 merged fund. The ICC Trave1 Grant Fund Ilormerly the International CperatiOn Fund) prowdes travel grants to young inveslig81ors presenting original work al the ICC. The fund was originally established through donations from the Japanese Society of Chemotherapy and Saloshi Omura. During 2024, travel awafds lotalling £4,525 wefe made from the fund,. however, these awaids weie incoirecuy charged to thè General Fund. The 2024 figures have therèfore bèèn restsled to COTreclly reff8cl the 811or2lion oflhese awards to the ICC Travel Grant Fund. Thè Endocardib"s and Blood8lr8am Infections IBSII Working Grovp Fund was established to support the 8clivilies ofthe Endocarditis and BlocstreaM Infe¢tions Working Group, which aimed lo provide education in the fields olepidemiology, palhogenesis, diagnosis gnd tnanagefflenl of blood51r88m infections Ihiough conference5, confeience proceedings and coordinated re888rch initiatives. As th8 BSI Working Group no longei exists, this design8led fund was discontinued during the year. The remaining nd balan was therefore transferred to unreslricled funds. The Urinary Tract Inlecbon IUTII Working Group co-ordinates various aspects ol UTI management and clinic deusion making, on a broad inleinalional base. 17. RELATED PARTY TRANSACTIONS Ther8 were no related paty transactions during the perioJ12024.' none). Page 21